| 000 | 01489 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518042140.0 | ||
| 264 | 0 | _c20191230 | |
| 008 | 201912s 0 0 eng d | ||
| 022 | _a2768-6698 | ||
| 024 | 7 |
_a10.2741/4772 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGuo, Jun-Xiu | |
| 245 | 0 | 0 |
_aBioactivity and safety of chimeric switch receptor T cells in glioblastoma patients. _h[electronic resource] |
| 260 |
_bFrontiers in bioscience (Landmark edition) _c06 2019 |
||
| 300 |
_a1158-1166 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBrain Neoplasms _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlioblastoma _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy, Adoptive _xmethods |
| 650 | 0 | 4 |
_aInterferon-gamma _xblood |
| 650 | 0 | 4 |
_aInterleukin-6 _xblood |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 |
_aReceptors, Chimeric Antigen _ximmunology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aWu, Chen-Xing | |
| 700 | 1 | _aWang, Peng-Fei | |
| 700 | 1 | _aLi, Zhong-Jun | |
| 700 | 1 | _aHan, Song | |
| 700 | 1 | _aJin, Wen | |
| 700 | 1 | _aLin, Zhi-Xiong | |
| 773 | 0 |
_tFrontiers in bioscience (Landmark edition) _gvol. 24 _gno. 6 _gp. 1158-1166 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2741/4772 _zAvailable from publisher's website |
| 999 |
_c29737588 _d29737588 |
||